POXEL Announces Successful Results for Imeglimin Phase 1 Study in Japanese Subjects and Appoints Dr. Yohjiro Itoh to Lead its Regulatory and Clinical Operations in Asia May 27, 2015
Noah D. Beerman Joins POXEL as Executive Vice President, Business Development and President, US Operations May 19, 2015
Poxel 2014 Annual Results in Line with a Major Post-Closing Event: the Successful Company IPO in February 2015 Apr 30, 2015
Poxel Announces Positive Top Line Results for Its Antidiabetic Agent Imeglimin in a Phase 2b Dose-Ranging Trial Dec 17, 2014
Poxel’s Anti-diabetic Imeglimin Confirms Its Unique Mechanism of Action in Type 2 Diabetic Patients Oct 7, 2013
